Advertisement

---

PROMETHEUS LABORATORIES INC.

Prometheus Laboratories Launches PROCLIVITY 02, a Phase IV Multi-Center Study Comparing the Sequence of Proleukin® (Aldesleukin for Injection) and Yervoy® (Ipilimumab) in Patients with Metastatic Melanoma

[2013-05-30] - PROCLIVITYSM (PROLEUKIN® Combined with IpiLImumab, Vemurafenib or other targeted agents In the Treatment of MalignancY)
PROCLIVITY 01 trial passes initial safety milestone


Prometheus Laboratories Presents New Data On Growing IBD Diagnostic Portfolio At Digestive Disease Week 2013

[2013-05-22] - - New data demonstrate a critical relationship between antibodies to adalimumab (ATA) and clinical response in IBD patients -
- Encouraging body of data further support standardized use of liquid phase assays in managing loss of treatment response among IBD patients using infliximab and adalimumab -


Prometheus Laboratories Inc. Launches PROCLIVITY(SM) 01 Clinical Trial of Proleukin® (Aldesleukin for Injection) Plus Vemurafenib Therapy in Patients with Metastatic Melanoma

[2013-05-09] - Multi-Center Study Represents Beginning of PROCLIVITY(SM) Clinical Trial Program
(PROLEUKIN® Combined with IpiLImumab, Vemurafenib or other targeted agents In the Treatment of MalignancY)


Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers